Lenalidomide treatment in lower risk myelodysplastic syndromes—The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients)-Reference-Cited by-同舟云学术

Lenalidomide treatment in lower risk myelodysplastic syndromes—The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients)

Published:2018-06 Issue: Volume:69 Page:12-17
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Jonasova Anna,Neuwirtova Radana,Polackova Helena,Siskova Magda,Stopka Tomas,Cmunt Eduard,Belickova Monika,Moudra Alena,Minarik Lubomir,Fuchs Ota,Michalova Kyra,Zemanova Zuzana

Funder

Czech Ministry of Health and institutional resources

SVV

GAUK

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference29 articles.

1. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients;Haase;Blood,2007

2. Efficacy of lenalidomide in myelodysplastic syndromes;List;N. Engl. J. Med.,2005

3. Deletion of the long arm but not the 5q31 region of chromosome 5 in myeloid malignancies;Brezinova;Leuk. Res.,2012

4. Thrombocytopenia at diagnosis as an important negative prognostic marker in isolated 5q- MDS (IPSS low and intermediate-1);Jonasova;Leuk. Res.,2012

5. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q;Mallo;Leukemia,2011

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myelodysplastic Syndrome;Comprehensive Hematology and Stem Cell Research;2024

2. Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes;International Journal of Molecular Sciences;2020-05-08

3. Introductory Chapter: Progress in Myelodysplastic Syndrome Area;Recent Developments in Myelodysplastic Syndromes;2019-02-20

4. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs;Cardiovascular & Hematological Disorders-Drug Targets;2019-01-28